Yasuhiro Hayashi
Overview
Explore the profile of Yasuhiro Hayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nakahara Y, Mitsui J, Date H, Porto K, Hayashi Y, Yamashita A, et al.
medRxiv
. 2023 Jul;
PMID: 37425910
To elucidate the molecular basis of multiple system atrophy (MSA), a neurodegenerative disease, we conducted a genome-wide association study (GWAS) in a Japanese MSA case/control series followed by replication studies...
12.
Hayashi Y, Huang X, Tanikawa T, Tanigawa K, Yamamoto M, Gohda J, et al.
J Biochem
. 2023 Mar;
173(5):337-342.
PMID: 36888972
N-(4-hydroxyphenyl)-retinamide (4-HPR) inhibits the dihydroceramide Δ4-desaturase 1 (DEGS1) enzymatic activity. We previously reported that 4-HPR suppresses the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) spike protein-mediated membrane fusion through a decrease...
13.
Tanikawa T, Kitamura M, Hayashi Y, Tomida N, Uwaya A, Isami F, et al.
In Vivo
. 2023 Mar;
37(2):591-595.
PMID: 36881078
Background/aim: The inflammatory response plays an important role in the activation and progression of many inflammation-related diseases. Cannabis sativa and Morinda citrifolia have long been used in folk medicine to...
14.
Hayashi Y, Matsuda K, Tanigawa K, Tanikawa T, Maeda K, Tsuchiya K
Biol Pharm Bull
. 2022 Oct;
45(10):1559-1563.
PMID: 36184516
Dihydroceramide Δ4-desaturase 1 (DEGS1) enzymatic activity is inhibited with N-(4-hydroxyphenyl)-retinamide (4-HPR). We reported previously that 4-HPR suppresses severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry through a DEGS1-independent mechanism. However,...
15.
Tanigawa K, Kiriya M, Hayashi Y, Shinden Y, Kijima Y, Natsugoe S, et al.
Biochim Biophys Acta Mol Cell Biol Lipids
. 2022 Apr;
1867(8):159164.
PMID: 35462067
Breast cancer is primarily classified into ductal and lobular types, as well as into noninvasive and invasive cancer. Invasive cancer involves lymphatic and hematogenous metastasis. In breast cancer patients with...
16.
Tanikawa T, Kitamura M, Hayashi Y, Yokogawa T, Inoue Y
In Vivo
. 2022 Jan;
36(1):227-232.
PMID: 34972719
Background/aim: The cannabinoid 2 (CB2) receptor is an important regulator of immunoinflammatory responses. Crude drugs commonly used in Japanese traditional Kampo medicine have displayed anti-inflammatory effects; however, few studies have...
17.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T
Am J Nephrol
. 2021 Nov;
52(12):977-978.
PMID: 34727543
No abstract available.
18.
Akizawa T, Yamada T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, et al.
Kidney Int Rep
. 2021 Oct;
6(10):2604-2616.
PMID: 34622100
Introduction: Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study....
19.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T
Am J Nephrol
. 2021 Sep;
52(10-11):871-883.
PMID: 34569489
Introduction: Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney...
20.
Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T
Am J Nephrol
. 2021 Sep;
52(10-11):884-893.
PMID: 34569482
Introduction: Erythropoiesis-stimulating agents (ESAs) are the current standard of care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis. Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase...